https://scholars.lib.ntu.edu.tw/handle/123456789/496073
標題: | Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes | 作者: | CHIN-HSIAO TSENG | 關鍵字: | Incretin; National Health Insurance; Pancreatic cancer; Sitagliptin; Taiwan | 公開日期: | 2016 | 出版社: | Blackwell Publishing Ltd | 卷: | 46 | 期: | 1 | 起(迄)頁: | 70-79 | 來源出版物: | European Journal of Clinical Investigation | 摘要: | Background: The risk of pancreatic cancer associated with incretin-based therapies is controversial. Methods: This study retrospectively analysed the National Health Insurance database including patients with newly diagnosed type 2 diabetes mellitus at an age ? 25 years between 1999 and 2010. A total of 71 137 ever users of sitagliptin and 933 046 never users were followed for pancreatic cancer until 31 December 2011. A time-dependent approach was used to calculate incidence and estimate hazard ratios adjusted for propensity score using Cox regression. Results: During follow-up, 83 ever users and 3658 never users developed pancreatic cancer, representing an incidence of 73·6 and 55·0 per 100 000 person-years, respectively. The adjusted hazard ratio (95% confidence intervals) for ever versus never users was 1·40 (1·13-1·75). The respective adjusted hazard ratio for the first, second and third tertile of cumulative dose < 14 700, 14 700-33 700 and > 33 700 mg was 1·83 (1·28-2·62), 1·97 (1·41-2·76) and 0·72 (0·45-1·15). For average daily dose of < 50, 50-99·9 and ? 100 mg, the respective hazard ratio was 3·10 (1·17-8·26), 1·01 (0·63-1·61) and 1·53 (1·18-1·97). Conclusions: Sitagliptin is significantly associated with a higher risk of pancreatic cancer, especially when the cumulative dose is < 33 700 mg. The risk diminished in users with a higher cumulative dose. The daily dose of sitagliptin should better be kept < 100 mg, and its use should be reconsidered in patients who suffer from severe renal impairment and thus a daily dose of < 50 mg is always recommended. Future studies are required to confirm the findings with more appropriate adjustment for smoking. ? 2016 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955214680&doi=10.1111%2feci.12570&partnerID=40&md5=d1df6f677ce74c2a02762677552c1ade https://scholars.lib.ntu.edu.tw/handle/123456789/496073 |
ISSN: | 0014-2972 | DOI: | 10.1111/eci.12570 | SDG/關鍵字: | sitagliptin; antidiabetic agent; sitagliptin; adult; Article; cancer incidence; cancer risk; controlled study; female; follow up; hazard ratio; human; major clinical study; male; non insulin dependent diabetes mellitus; pancreas cancer; priority journal; propensity score; retrospective study; aged; carcinoma; Carcinoma, Pancreatic Ductal; case control study; Diabetes Mellitus, Type 2; incidence; middle aged; Pancreatic Neoplasms; proportional hazards model; risk factor; Taiwan; Adult; Aged; Carcinoma; Carcinoma, Pancreatic Ductal; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pancreatic Neoplasms; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sitagliptin Phosphate; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。